This means that if you inject 5 mg of tirzepatide on Monday: By Saturday (day 5), approximately 2.5 mg equivalent remains in circulation By the following Monday (day 7), approximately 1.9 mg equivalent remains When you inject the next 5 mg dose on Monday, it adds to the 1.9 mg still circulating By week 4 of consistent weekly dosing, you reach steady state, where the amount you inject each week equals the amount eliminated
Mild Side Effects Patients may occasionally experience: Nausea Mild headache Injection site discomfort These effects are usually temporary and resolve quickly
GLP-1 Receptor Agonist GLP-1, or glucagon-like peptide-1, is a hormone that plays a vital role in controlling blood sugar and appetite
Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved and removed from the FDAs shortage list, see our prior blog GLP-1 Drugs: FDA Removes Lillys Zepbound and Mounjaro (tirzepatide injection) from its Drug Shortage List, on October 8, 2024, the Outsourcing Facilities Association (OFA) a trade association representing FDA-registered 503B outsourcing facilities filed a lawsuit against the FDA relating to the agencys removal of tirzepatide, from the FDAs drug shortage list